Cellebrite DI Ltd. (NASDAQ:CLBT) Receives $23.43 Consensus Price Target from Analysts

Cellebrite DI Ltd. (NASDAQ:CLBT) has been assigned a consensus rating of “Buy” from the seven research firms that are currently covering the company, Marketbeat reports. Seven investment analysts have rated the stock with a buy rating. The average 1-year price objective among brokerages that have covered the stock in the last year is $23.43.

Several research firms recently weighed in on CLBT. JPMorgan Chase & Co. upped their price objective on shares of Cellebrite DI from $24.00 to $28.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 11th. Needham & Company LLC reiterated a “buy” rating and set a $28.00 price target on shares of Cellebrite DI in a research report on Monday, March 10th. Finally, Lake Street Capital upped their target price on Cellebrite DI from $17.00 to $26.00 and gave the stock a “buy” rating in a research note on Friday, February 14th.

Institutional Investors Weigh In On Cellebrite DI

Several hedge funds have recently modified their holdings of CLBT. True Wind Capital Management L.P. raised its position in Cellebrite DI by 18.2% in the fourth quarter. True Wind Capital Management L.P. now owns 13,861,007 shares of the company’s stock valued at $305,358,000 after purchasing an additional 2,130,386 shares during the last quarter. FMR LLC increased its stake in shares of Cellebrite DI by 89.1% in the fourth quarter. FMR LLC now owns 10,621,344 shares of the company’s stock valued at $233,988,000 after buying an additional 5,004,587 shares during the period. Axon Enterprise Inc. bought a new position in Cellebrite DI in the 4th quarter valued at approximately $198,270,000. Voss Capital LP boosted its position in Cellebrite DI by 1.2% during the 4th quarter. Voss Capital LP now owns 3,240,000 shares of the company’s stock worth $71,377,000 after buying an additional 39,700 shares during the period. Finally, Pertento Partners LLP grew its holdings in Cellebrite DI by 26.7% during the 4th quarter. Pertento Partners LLP now owns 2,975,374 shares of the company’s stock worth $65,547,000 after acquiring an additional 626,373 shares during the last quarter. Institutional investors and hedge funds own 45.88% of the company’s stock.

Cellebrite DI Stock Performance

CLBT stock opened at $20.61 on Friday. Cellebrite DI has a 52 week low of $10.25 and a 52 week high of $26.30. The company’s 50-day simple moving average is $21.04 and its 200 day simple moving average is $19.85. The company has a market capitalization of $4.94 billion, a PE ratio of -14.83, a price-to-earnings-growth ratio of 4.27 and a beta of 1.52.

Cellebrite DI (NASDAQ:CLBT) last issued its quarterly earnings results on Thursday, February 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. On average, analysts forecast that Cellebrite DI will post 0.3 EPS for the current year.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.